CompletedNCT01400113
Asenapine or Placebo for Acute Agitation
About this title
Read the official source — NCT01400113Medication studyAges 18–65United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- SyracuseSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- Unity Health Toronto
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01400113
- Official title
Show the full official title
Treating Acutely Agitated Patients With Asenapine Sublingual Tablets: A Single-Dose, Randomized, Double-Blind Placebo Controlled Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Syracuse
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Unity Health Toronto.
Did this study involve medication?
Yes. The study involved medication, including Asenapine and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
